Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 19Recruiting 8Terminated 7Active not recruiting 3Unknown 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 10Gynecologic 5Genitourinary 4Endocrine 4NET 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Multiple Endocrine Neoplasia Type 1 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

lutetium Lu 177 dotatate 13Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 4Octreotide 3Lutetium-177 3Ipilimumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1pasireotide 1fludarabine phosphate 1fludarabine 1entrectinib 1copper dotatate CU-64 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Everolimus × NET × Clear all
NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting
324 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
36 enrolled
EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡